ent-03
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 13, 2023 (NCT05925920)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Protein-tyrosine phosphatase 1BINHIBITOR
PTPN1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC(CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@H]4C[C@@H](NCCCNCCCCNCCCN)CC[C@]4(C)[C@H]3CC[C@]12C)C(=O)O- Mol. weight
- 618.99 g/mol
- Lipinski Ro5
- 3 violation(s)
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314916 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05925920 | Phase 1 | Jun 13, 2023 | Enterin Inc. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Enterin Inc. | For profit | 1 | 1 | 1 | 2023 |
1 organizations
Page 1 / 1